Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Chikara Murakata is active.

Publication


Featured researches published by Chikara Murakata.


Biochemical and Biophysical Research Communications | 1987

K-252 compounds, novel and potent inhibitors of protein kinase C and cyclic nucleotide-dependent protein kinases.

Hiroshi Kase; Kazuyuki Iwahashi; Satoshi Nakanishi; Yuzuru Matsuda; Koji Yamada; Mitsuru Takahashi; Chikara Murakata; Akira Sato; Masami Kaneko

K-252 compounds (K-252a and b isolated from Nocardiopsis sp. (1) and their synthetic derivatives) were found to inhibit cyclic nucleotide-dependent protein kinases and protein kinase C to various extents. The inhibitions were of the competitive type with respect to ATP. K-252a was a non-selective inhibitor for these three protein kinases with Ki values 18-25 nM. K-252b showed a comparable potency for protein kinase C (Ki, 20nM), whereas inhibitory potencies for cyclic nucleotide-dependent protein kinases were reduced. KT5720 and KT5822 selectively inhibited cAMP-dependent (Ki, 60nM) and cGMP-dependent (Ki, 2.4nM) protein kinases, respectively.


The Journal of Neuroscience | 2000

Rescue of Hearing, Auditory Hair Cells, and Neurons by CEP-1347/KT7515, an Inhibitor of c-Jun N-Terminal Kinase Activation

Ulla Pirvola; Liang Xing-Qun; Jussi Virkkala; Mart Saarma; Chikara Murakata; Anna Marie Camoratto; Kevin M. Walton; Jukka Ylikoski


Clinical Cancer Research | 1998

Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587).

Craig A. Dionne; Anna Marie Camoratto; Jitesh P. Jani; Erling O. Emerson; Nicola Neff; Jeffry L. Vaught; Chikara Murakata; Daniel Djakiew; John Lamb; Steve Bova; Daniel J. George; John T. Isaacs


Journal of Medicinal Chemistry | 1997

Neurotrophic 3,9-bis[(alkylthio)methyl]-and-bis(alkoxymethyl)-K-252a derivatives.

Masami Kaneko; Yutaka Saito; Hiromitsu Saito; Tadashi Matsumoto; Yuzuru Matsuda; Jeffry L. Vaught; Craig A. Dionne; Thelma S. Angeles; Marcie A. Glicksman; Nicola Neff; David P. Rotella; James C. Kauer; John P. Mallamo; Robert L. Hudkins; Chikara Murakata


Archive | 1995

Protein kinase inhibitors for treatment of neurological disorders

Michael E. Lewis; James C. Kauer; Nicola Neff; Jill Roberts-Lewis; Chikara Murakata; Hiromitsu Saito; Yuzuru Matsuda; Marcie A. Glicksman; Fumihiko Kanai; Masami Kaneko


Archive | 1993

Selected protein kinase inhibitors for the treatment of neurological disorders

Michael E. Lewis; James C. Kauer; Nicola Neff; Jill Roberts-Lewis; Chikara Murakata; Hiromitsu Saito; Yuzuru Matsuda; Marcie A. Glicksman


Archive | 1994

Use of indolocarbazole derivatives to treat a pathological condition of the prostate

Craig A. Dionne; Patricia C. Contreras; Chikara Murakata


Archive | 1993

K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders

Marcie A. Glicksman; David P. Rotella; Nicola Neff; Chikara Murakata


Archive | 1994

K-252a derivatives for treatment of neurological disorders

Michael E. Lewis; James C. Kauer; Nicola Neff; Jill Roberts-Lewis; Chikara Murakata; Hiromitsu Saito; Yuzuru Matsuda; Marcie A. Glicksman; Fumihiko Kanai; Masami Kaneko


Archive | 1994

K-252 derivatives which enhance neurotrophin-induced activity

Marcie A. Glicksman; Robert L. Hudkins; David P. Rotella; Nicola Neff; Chikara Murakata

Collaboration


Dive into the Chikara Murakata's collaboration.

Researchain Logo
Decentralizing Knowledge